Trial · NCT05108935
Providing PrEP, Hepatitis C Treatment, and MOUD Through Telemedicine at Greensboro SSP
NCT05108935, Not applicable, Completed, Duke University
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Providing PrEP, Hepatitis C Treatment, and MOUD Through Telemedicine at Greensboro SSP. Trials, record NCT05108935. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05108935
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Providing PrEP, Hepatitis C Treatment, and MOUD Through Telemedicine at Greensboro SSP
- NCT number
- NCT05108935
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 17 participants, actual
- Lead sponsor
- Duke University
- Conditions
- Opioid Use, Opioid Use Disorder, Risk Reduction, Hiv, Hepatitis C
- Interventions
- Suboxone, Truvada, Mavyret
- First posted
- 2021-11-05
- Last updated
- 2023-04-27
Source ClinicalTrials.gov
Registered outcomes17
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Proportion who demonstrate no or minimal opioid use. | 3 months | Defined as self-reported opioid use on ≤4 days in the past month and/or 2 or more consecutive negative urine tests. |
| Primary | Proportion who demonstrate no or minimal opioid use. | 6 months | Defined as self-reported opioid use on ≤4 days in the past month and/or 2 or more consecutive negative urine tests. |
| Primary | Proportion who remain HIV negative. | 3 months | Measured via negative HIV test. |
| Primary | Proportion who remain HIV negative. | 6 months | Measured via negative HIV test. |
| Primary | Among participants who undergo hepatitis C treatment, the hepatitis C cure rate | 6 months | Measured via negative hepatitis C test. |
| Primary | Persistence in care | 3 months | Defined as the proportion who remain on treatment. |
| Primary | Persistence in care | 6 months | Defined as the proportion who remain on treatment. |
| Primary | Ease/difficulty of visiting a SSP to meet with a provider via telemedicine | month 1 | Exploratory method, conducted in the form of individual interviews to document the personal experiences of each participant (qualitative method) |
| Primary | Ease/difficulty of visiting a SSP to meet with a provider via telemedicine | month 6 | Exploratory method, conducted in the form of individual interviews to document the personal experiences of each participant (qualitative method) |
| Primary | Ease/difficulty of accessing the telemedicine video platform | month 1 | Exploratory method, conducted in the form of individual interviews to document the personal experiences of each participant (qualitative method) |
1 to 10 of 17Source ClinicalTrials.gov
See all 17 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| P30AI064518 | Center for AIDS Research | TOMARAS, GEORGIA DORIS; NAGGIE, SUSANNA | DUKE UNIVERSITY | NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES | 2005 to 2025 |
Source NIH RePORTER
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05108935
GET https://conductscience.org/api/trials/v1/NCT05108935/registered